Literature DB >> 34314176

Multiplex Mass Spectrometry Analysis of Amyloid Proteins in Human Plasma for Alzheimer's Disease Diagnosis.

Weimin Ni1, William Jagust2,3, Daojing Wang1.   

Abstract

Direct analysis of amyloid proteins in human plasma will promote rapid screening of brain amyloidosis, the earliest pathological signature of Alzheimer's disease. We developed a microflow liquid chromatography-targeted mass spectrometry assay for quantitation of four intact β-amyloid proteins starting from 1 mL of human plasma samples. This method showed 90% accuracy for predicting brain amyloid using plasma Aβ42/Aβ40 values from 36 cognitively normal individuals in a prospective clinical study (raw data deposited in MassIVE, Data set ID MSV000087451). Our method may contribute to early diagnosis of Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34314176      PMCID： PMC8699791          DOI： 10.1021/acs.jproteome.1c00424

Source DB:  PubMed          Journal:  J Proteome Res        ISSN： 1535-3893            Impact factor:   5.370


  23 in total

1.  Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer.

Authors:  Sebastien Gallien; Elodie Duriez; Catharina Crone; Markus Kellmann; Thomas Moehring; Bruno Domon
Journal:  Mol Cell Proteomics       Date:  2012-09-07       Impact factor: 5.911

Review 2.  Alzheimer's disease: the challenge of the second century.

Authors:  David M Holtzman; John C Morris; Alison M Goate
Journal:  Sci Transl Med       Date:  2011-04-06       Impact factor: 17.956

3.  Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline.

Authors:  Kristine Yaffe; Andrea Weston; Neill R Graff-Radford; Suzanne Satterfield; Eleanor M Simonsick; Steven G Younkin; Linda H Younkin; Lewis Kuller; Hilsa N Ayonayon; Jingzhong Ding; Tamara B Harris
Journal:  JAMA       Date:  2011-01-19       Impact factor: 56.272

4.  Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.

Authors:  Sylvia Villeneuve; Gil D Rabinovici; Brendan I Cohn-Sheehy; Cindee Madison; Nagehan Ayakta; Pia M Ghosh; Renaud La Joie; Samia Kate Arthur-Bentil; Jacob W Vogel; Shawn M Marks; Manja Lehmann; Howard J Rosen; Bruce Reed; John Olichney; Adam L Boxer; Bruce L Miller; Ewa Borys; Lee-Way Jin; Eric J Huang; Lea T Grinberg; Charles DeCarli; William W Seeley; William Jagust
Journal:  Brain       Date:  2015-05-06       Impact factor: 13.501

5.  Top-down proteomics: challenges, innovations, and applications in basic and clinical research.

Authors:  Kyle A Brown; Jake A Melby; David S Roberts; Ying Ge
Journal:  Expert Rev Proteomics       Date:  2020-12-17       Impact factor: 3.940

6.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.

Authors:  Sebastian Palmqvist; Shorena Janelidze; Yakeel T Quiroz; Henrik Zetterberg; Francisco Lopera; Erik Stomrud; Yi Su; Yinghua Chen; Geidy E Serrano; Antoine Leuzy; Niklas Mattsson-Carlgren; Olof Strandberg; Ruben Smith; Andres Villegas; Diego Sepulveda-Falla; Xiyun Chai; Nicholas K Proctor; Thomas G Beach; Kaj Blennow; Jeffrey L Dage; Eric M Reiman; Oskar Hansson
Journal:  JAMA       Date:  2020-08-25       Impact factor: 56.272

7.  Robust, reproducible and quantitative analysis of thousands of proteomes by micro-flow LC-MS/MS.

Authors:  Yangyang Bian; Runsheng Zheng; Florian P Bayer; Cassandra Wong; Yun-Chien Chang; Chen Meng; Daniel P Zolg; Maria Reinecke; Jana Zecha; Svenja Wiechmann; Stephanie Heinzlmeir; Johannes Scherr; Bernhard Hemmer; Mike Baynham; Anne-Claude Gingras; Oleksandr Boychenko; Bernhard Kuster
Journal:  Nat Commun       Date:  2020-01-09       Impact factor: 14.919

8.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.

Authors:  Suzanne E Schindler; James G Bollinger; Vitaliy Ovod; Kwasi G Mawuenyega; Yan Li; Brian A Gordon; David M Holtzman; John C Morris; Tammie L S Benzinger; Chengjie Xiong; Anne M Fagan; Randall J Bateman
Journal:  Neurology       Date:  2019-08-01       Impact factor: 11.800

9.  Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  Elisabeth H Thijssen; Renaud La Joie; Amy Wolf; Amelia Strom; Ping Wang; Leonardo Iaccarino; Viktoriya Bourakova; Yann Cobigo; Hilary Heuer; Salvatore Spina; Lawren VandeVrede; Xiyun Chai; Nicholas K Proctor; David C Airey; Sergey Shcherbinin; Cynthia Duggan Evans; John R Sims; Henrik Zetterberg; Kaj Blennow; Anna M Karydas; Charlotte E Teunissen; Joel H Kramer; Lea T Grinberg; William W Seeley; Howie Rosen; Bradley F Boeve; Bruce L Miller; Gil D Rabinovici; Jeffrey L Dage; Julio C Rojas; Adam L Boxer
Journal:  Nat Med       Date:  2020-03-02       Impact factor: 53.440

10.  Development and Technical Validation of an Immunoassay for the Detection of APP669-711 (Aβ-3-40) in Biological Samples.

Authors:  Hans W Klafki; Petra Rieper; Anja Matzen; Silvia Zampar; Oliver Wirths; Jonathan Vogelgsang; Dirk Osterloh; Lara Rohdenburg; Timo J Oberstein; Olaf Jahn; Isaak Beyer; Ingolf Lachmann; Hans-Joachim Knölker; Jens Wiltfang
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923
View more
  1 in total

1.  A Rapid LC-MS/MS-PRM Assay for Serologic Quantification of Sialylated O-HPX Glycoforms in Patients with Liver Fibrosis.

Authors:  Aswini Panigrahi; Julius Benicky; Renhuizi Wei; Jaeil Ahn; Radoslav Goldman; Miloslav Sanda
Journal:  Molecules       Date:  2022-03-29       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.